A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00931840. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2, multicenter, multiple-arm, open-label study to evaluate the efficacy, safety, and tolerability of EZN-2208. EZN-2208 will be administered as a single agent in patients with K-RAS mutations in the tumors. Patients with wild type K-RAS in tumors will be randomized to EZN-2208 + cetuximab or to standard of care (Camptosar® + cetuximab), patients must have failed regimens containing irinotecan (Camptosar®, CPT-11), oxaliplatin (Eloxatin®), and fluoropyrimidine. After discontinuation of study treatment, patients will receive care as considered appropriate by the investigator. Patients will continue to be followed for disease progression, subsequent anticancer therapy, and survival.
Study identification
- NCT ID
- NCT00931840
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 220 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2009 (Type not available)
- Primary completion
- Oct 2011 (Estimated)
- Completion
- Jan 2012 (Estimated)
- Last update posted
- Sep 20, 2011
2009 – 2012
United States locations
- U.S. sites
- 35
- U.S. states
- 16
- U.S. cities
- 33
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Location #033 | Tucson | Arizona | 85724-5024 | — |
| Location# 042 | Alhambra | California | 91801 | — |
| Location # 043 | Bakersfield | California | 93309 | — |
| Location# 044 | Fullerton | California | 92835 | — |
| Location# 019 | La Jolla | California | 92093-0698 | — |
| Location# 046 | Long Beach | California | 90813 | — |
| Location# 053 | Los Angeles | California | 90095 | — |
| Location# 051 | Northridge | California | 91235 | — |
| Location# 045 | Pomona | California | 91767 | — |
| Location # 048 | Santa Barbara | California | 93105 | — |
| Location # 049 | Santa Barbara | California | 93105 | — |
| Location# 052 | Santa Maria | California | 93454 | — |
| Location #027 | Stanford | California | 94305 | — |
| Location# 003 | Newark | Delaware | 19718 | — |
| Location# 047 | Orlando | Florida | 32804 | — |
| Location# 022 | Port Saint Lucie | Florida | 34952 | — |
| Location# 005 | Marietta | Georgia | 30060 | — |
| Location# 009 | Chicago | Illinois | 60611-2927 | — |
| Location #050 | Terre Haute | Indiana | 47802 | — |
| Location# 029 | Worcester | Massachusetts | 01655 | — |
| Location #031 | Lebanon | New Hampshire | 03756 | — |
| Location # 030 | Buffalo | New York | 14263 | — |
| Location# 035 | New York | New York | 10003 | — |
| Location# 002 | New York | New York | 10016 | — |
| Location# 007 | The Bronx | New York | 10461 | — |
| Location# 001 | Chapel Hill | North Carolina | 27514 | — |
| Location# 020 | Goldsboro | North Carolina | 27534 | — |
| Location# 024 | Winston-Salem | North Carolina | 27103 | — |
| Location# 008 | Columbus | Ohio | 43210 | — |
| Location# 037 | Lancaster | Pennsylvania | 17605 | — |
| Location# 018 | Greenville | South Carolina | 29615 | — |
| Location# 004 | Memphis | Tennessee | 38138 | — |
| Location #038 | Houston | Texas | 77584 | — |
| Location# 011 | Lubbock | Texas | 79410 | — |
| Location# 021 | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00931840, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 20, 2011 · Synced Nov 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.